Search clinical trials for: Nivolumab cohort 1

Total 17945 results

Gilead Sciences

Terminated

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma

Japan
Medical College of Wisconsin

Recruiting

MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer

Rectal Adenocarcinoma

United States
Chinese PLA General Hospital

Unknown

Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs

Biliary Tract Cancer

China
Erol Olcok Corum Training and Research Hospital

Completed

Anesthesia Preferences in the COVID-19 Pandemic: General Anesthesia or Regional Anesthesia?

COVID-19

Turkey
Yale University
AstraZeneca

Withdrawn

Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

Malignant Melanoma
Bristol-Myers Squibb

Completed

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors

Neoplasms by Site

United States
Italian Network for Tumor Biotherapy Foundation
Bristol-Myers Squibb; Astex Pharmaceuticals, Inc.

Not yet recruiting

A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 (NIBIT-ML1)

Melanoma | Non Small Cell Lung Cancer

Italy
Universitätsklinikum Köln
ZKS Köln

Withdrawn

Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients (CERAD-IMMUNE)

Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases
Rhythm Pharmaceuticals, Inc.

Recruiting

A Study of RM-718 in Healthy Subjects and in Patients With HO

Hypothalamic Obesity

United States
Eisai Inc.

Completed

Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

Thyroid Cancer

United States, Australia, France, Poland, United Kingdom, Italy
Mothaffar Rimawi

Terminated

CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer (CRIZENT)

Breast Cancer

United States
Kamari Pharma Ltd

Recruiting

Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC

Pachyonychia Congenita | Punctate Palmoplantar Keratoderma Type 1

United Kingdom
Bristol-Myers Squibb

Not yet recruiting

Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France (URADJ)

Urothelial Carcinoma

France
Meirav Kedmi MD

Recruiting

Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy (NivoM)

Lymphoma, B-Cell

Israel
Tan Tock Seng Hospital
Nanyang Technological University

Completed

SG Healthcare and Assistive Robotics Programme (SHARP) - Proof of Concept Study (SHARPCARE)

Stroke | Spinal Cord Injuries | Acquired Brain Injury | Traumatic Brain Injury With Loss of Consciousness | Joint Replacement Surgery

Singapore
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Stage IV Cervical Cancer AJCC v6 and v7 | Stage IVB Cervical Cancer AJCC v6 and v7

United States
HUYABIO International, LLC.

Completed

Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

Melanoma | Renal Cell Carcinoma | Non-Small Cell Lung Cancer

United States
The Clatterbridge Cancer Centre NHS Foundation...
Bristol-Myers Squibb; University of Liverpool

Active, not recruiting

CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer (NICO)

Squamous Cell Carcinoma of the Oral Cavity

United Kingdom
Wake Forest University

Completed

Effect Of Acute Inflammatory Mediators On Functional Limitations In Patients With Acute Respiratory Failure

Acute Respiratory Failure

United States
G2GBio, Inc.

Recruiting

Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics From Single Dose of Intramuscular (IM) and Subcutaneous (SC) Donepezil (GB-5001) Injections Versus Donepezil Oral Tablet (Aricept®) in Healthy Male Volunteers

Alzheimer Disease

Korea, Republic of
University Hospital Tuebingen

Recruiting

Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26) (IT-PD1)

Leptomeningeal Disease

Germany
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Completed

Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs

Advanced Stage Non-small Cell Lung Cancer

United States
UNICANCER
Bristol-Myers Squibb

Completed

Nivolumab in Recurrent and/or Metastatic SCCHN (TopNIVO)

Recurrent and/or Metastatic Platinum-refractory SCCHN

France
Akamis Bio
Bristol-Myers Squibb; Syneos Health

Completed

Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors (SPICE)

Colorectal Cancer | Squamous Cell Carcinoma of the Head and Neck | Epithelial Tumor

United States
Fukushima Medical University
Kanagawa Cancer Center

Unknown

Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)

Gastric Cancer

Japan
Kurume University
Eisai Inc.; Mebix Inc

Completed

An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Transitioning to Lemborexant in Japanese Subjects With Insomnia

Insomnia

Japan
Erasmus Medical Center

Recruiting

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Immunotherapy | Melanoma Stage IV | Melanoma Stage III | Toxicity, Drug

Netherlands
Yonsei University

Recruiting

Nivolumab for Recurrent/Metastatic Carcinosarcoma

Recurrent/Metastatic Carcinosarcoma

Korea, Republic of
Bristol-Myers Squibb

Active, not recruiting

An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia

Melanoma

Australia
Yonsei University

Completed

A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC Patients

Non -Small Cell Lung Cancer

Korea, Republic of
Bristol-Myers Squibb

Active, not recruiting

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Neoplasms by Site

United States, Australia, Denmark, France, Switzerland, Austria, Canada, Germany, Japan, Netherlands, Norway, Spain, United Kingdom, Finland, Italy
Asan Medical Center
Samsung Medical Center; Bundang CHA Hospital

Completed

Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma (RENOBATE)

Carcinoma, Hepatocellular | Hepatoma

Korea, Republic of
Amsterdam UMC, location VUmc
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction (NeoNivo)

Oral Cavity Squamous Cell Carcinoma

Netherlands
Center for Epidemiology and Health Research, Germany
Abbott Products Operations AG

Terminated

Maternal and Newborn Safety Profile of Progestogens in EARLY Pregnancy (PEARLY)

Early Pregnancy Bleeding | Recurrent Pregnancy Loss

Germany
Weill Medical College of Cornell University
Bristol-Myers Squibb

Active, not recruiting

Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)

Gastroesophageal Adenocarcinoma

United States
Bristol-Myers Squibb

Completed

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies (MDX1106-01)

Carcinoma, Non-Small-Cell Lung | Colorectal Cancer | Prostate Cancer | Renal Cancer | Malignant Melanoma

United States
University Hospital, Ghent

Completed

Discovering the Effect of Venous Insufficiency on Nocturia (DEVINe)

Fluid Overload | Venous Insufficiency of Leg | Nocturia

Belgium
Lyudmila Bazhenova, M.D.
BeyondSpring Pharmaceuticals Inc.

Active, not recruiting

Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer Metastatic

United States
Clinica Universidad de Navarra, Universidad de...

Unknown

Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors (INTRUST)

Neoplasms

Spain
Royal Marsden NHS Foundation Trust

Unknown

A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR) (ADAPTeR)

Renal Cell Carcinoma

United Kingdom
PharmaEssentia

Recruiting

The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection

Chronic Hepatitis B Infection | Chronic Hepatitis D Infection

Taiwan
University of Milano Bicocca

Recruiting

The Natural History of Hospitalized COVID-19 Patients (STORM)

Sars-CoV2

Italy
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IV Colon Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Unresectable Colon Adenocarcinoma | Unresectable Rectal Adenocarcinoma

United States, Puerto Rico
Prof. Dr. med. Dirk Schadendorf

Completed

Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED

Malignant Melanoma

Germany
Replimune Inc.

Recruiting

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

Cancer

United Kingdom, Spain
University of Cologne

Recruiting

Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy (AERN)

Classical Hodgkin Lymphoma

Germany
Intergroupe Francophone de Cancerologie Thoracique
ANRS, Emerging Infectious Diseases

Completed

Immunotherapy by Nivolumab for HIV+ Patients (CHIVA2)

HIV/AIDS | Non Small Cell Lung Cancer Stage IIIB | Non Small Cell Lung Cancer Metastatic

France
Assistance Publique - Hôpitaux de Paris

Unknown

Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort. (CORIMUNO-NIVO)

COVID19- Infection With SARS-CoV-2 Virus

France
The Netherlands Cancer Institute
Bristol-Myers Squibb

Completed

Nivolumab in Patients With Recurrent Malignant Mesothelioma (NivoMes)

Malignant Pleural Mesothelioma
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Active, not recruiting

Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer

Colorectal Adenocarcinoma | Microsatellite Stable (MSS) Colorectal Adenocarcinomas

United States

Search clinical trials for: Nivolumab cohort 1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations